Streetbeat News

Stock Prices

MSI

Barclays analyst Tim Long has maintained an Overweight rating on Motorola Solutions (NYSE:MSI) and increased the price target from $333 to $352, indicating a positive outlook on the company's stock.

Portfolio Pulse from Benzinga Newsdesk

January 02, 2024 | 12:36 pm

COIN

GOOG

PINS

YELP

Insiders at Alphabet, Pinterest, Coinbase Global, and Yelp have recently sold shares of their companies. Alphabet's John Kent Walker sold shares worth around $4 million, Pinterest's Christine Deputy sold shares for approximately $837,108, Coinbase's Frederick Ernest Ehrsam III sold shares valued at around $850,245, and Yelp's Joseph Nachman sold shares for about $288,437. These sales could indicate various things, including personal financial management or a lack of confidence in the company's future prospects. However, insider sales are just one of many factors investors should consider.

Portfolio Pulse from Avi Kapoor

January 02, 2024 | 12:31 pm

PTVE

B of A Securities analyst George Staphos has upgraded Pactiv Evergreen (PTVE) from Neutral to Buy and increased the price target from $14 to $16. This upgrade suggests a positive outlook on PTVE's future performance and potential for stock price appreciation.

Portfolio Pulse from Benzinga Newsdesk

January 02, 2024 | 12:23 pm

AAPL

AOSL

BAC

CMG

EXPE

SPT

Wall Street analysts have updated their price targets and ratings for several companies. Antero Resources had its target cut by Raymond James, while Alpha and Omega Semiconductor received a boost from B. Riley Securities. Barclays downgraded Apple and raised its target for Morgan Stanley and Bank of America. Jefferies upgraded Park Hotels & Resorts, Piper Sandler downgraded Unity Software, Wells Fargo raised Expedia's target, Cantor Fitzgerald upgraded Sprout Social, and Stephens & Co. increased Chipotle's target.

Portfolio Pulse from Avi Kapoor

January 02, 2024 | 12:23 pm

PCCYF

XOM

Exxon Mobil Corp (XOM) has exited the West Qurna 1 oilfield in Iraq, transferring operations to PetroChina Co., Ltd. (PCCYF), which now becomes the lead contractor. The oilfield produces approximately 550,000 barrels per day and has over 20 billion barrels of estimated recoverable reserves. ExxonMobil's departure marks its exit from Iraq's energy sector, while PetroChina now holds the largest stake in the field. The deal was finalized in a meeting with senior Iraqi oil officials, ExxonMobil, PetroChina, and Basra Oil Co. ExxonMobil's shares are trading higher by 0.85% at $100.83 in premarket.

Portfolio Pulse from Lekha Gupta

January 02, 2024 | 12:20 pm

HRMY

B of A Securities analyst Jason Gerberry downgraded Harmony Biosciences (NASDAQ:HRMY) from Neutral to Underperform and set a price target of $30. This suggests a bearish outlook on the company's stock performance.

Portfolio Pulse from Benzinga Newsdesk

January 02, 2024 | 12:13 pm

STT

Barclays analyst Jason Goldberg has maintained an Overweight rating on State Street (NYSE:STT) and increased the price target from $87 to $102. This adjustment reflects a positive outlook on the company's stock.

Portfolio Pulse from Benzinga Newsdesk

January 02, 2024 | 12:07 pm

Piper Sandler analyst Brent Bracelin has downgraded BlackLine (NASDAQ:BL) from Neutral to Underweight while increasing the price target from $53 to $60. This suggests that while the analyst sees some upside potential in the stock's price, they believe the company may underperform the broader market or its sector.

Portfolio Pulse from Benzinga Newsdesk

January 02, 2024 | 12:06 pm

CORT

KTRA

MIST

MOTS

RPID

The article lists the top 5 oversold health care stocks with potential for gains in January, based on their low Relative Strength Index (RSI) values. Corcept Therapeutics (CORT), Kintara Therapeutics (KTRA), Rapid Micro Biosystems (RPID), Motus GI Holdings (MOTS), and Milestone Pharmaceuticals (MIST) are identified as major oversold players in the sector, with RSI values near or below 30, indicating they may be undervalued.

Portfolio Pulse from Avi Kapoor

January 02, 2024 | 12:06 pm

SNDX

Syndax Pharmaceuticals announced recent updates and anticipated milestones for 2024, including the potential launch of two products in the U.S. The company also completed a $230M follow-on offering in December, which they believe extends their financial runway through 2026. They are currently working with the FDA on regulatory submissions.

Portfolio Pulse from Benzinga Newsdesk

January 02, 2024 | 12:05 pm